MARKET

HOWL

HOWL

Werewolf Therapeutics, Inc.
NASDAQ
0.6702
-0.0490
-6.81%
After Hours: 0.6830 +0.0128 +1.91% 18:54 02/20 EST
OPEN
0.7250
PREV CLOSE
0.7192
HIGH
0.7350
LOW
0.6501
VOLUME
397.77K
TURNOVER
--
52 WEEK HIGH
2.380
52 WEEK LOW
0.5301
MARKET CAP
32.53M
P/E (TTM)
-0.4139
1D
5D
1M
3M
1Y
5Y
1D
Analysts Offer Insights on Healthcare Companies: Medtronic (MDT), Elanco Animal Health (ELAN) and Werewolf Therapeutics (HOWL)
TipRanks · 3d ago
Weekly Report: what happened at HOWL last week (0209-0213)?
Weekly Report · 4d ago
Werewolf Therapeutics to Cut 64% of Workforce, CFO Resigns
Dow Jones · 02/13 21:53
Werewolf Therapeutics Announces Major Workforce and Leadership Restructuring
TipRanks · 02/13 21:50
Werewolf Therapeutics announces 64% workforce reduction
TipRanks · 02/13 21:30
Werewolf Therapeutics Plans To Cut Workforce By 64%, To Record One-Time Charge In Q1 Of ~$4.1M; CFO Timothy W. Trost Resigns, Michael Urban Appointed Principal Financial Officer And Principal Accounting Officer
Benzinga · 02/13 21:26
WEREWOLF THERAPEUTICS INC - TO REDUCE WORKFORCE BY 64% - SEC FILING
Reuters · 02/13 21:21
WEREWOLF THERAPEUTICS INC - MICHAEL URBAN APPOINTED PRINCIPAL FINANCIAL AND ACCOUNTING OFFICER - SEC FILING
Reuters · 02/13 21:21
More
About HOWL
Werewolf Therapeutics, Inc. is a biopharmaceutical company engaged in the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions. It is leveraging its PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. The Company’s advanced clinical-stage product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2) and IL-12 INDUKINE molecules for the treatment of solid tumors. It is advancing WTX-124 in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor. It is advancing WTX-712, WTX-518, and WTX-921 through preclinical development.

Webull offers Werewolf Therapeutics Inc stock information, including NASDAQ: HOWL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HOWL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading HOWL stock methods without spending real money on the virtual paper trading platform.